Mark Lackner - Zentalis PharmaceuticalsL Chief Strategy
| ZNTL Stock | USD 11.77 0.80 6.36% |
Insider
Mark Lackner is Chief Strategy of Zentalis PharmaceuticalsLlc
| Age | 56 |
| Address | 1359 Broadway, New York, NY, United States, 10018 |
| Phone | 212 433 3791 |
| Web | https://zentalis.com |
Zentalis PharmaceuticalsL Management Efficiency
The company has return on total asset (ROA) of (0.2853) % which means that it has lost $0.2853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6709) %, meaning that it created substantial loss on money invested by shareholders. Zentalis PharmaceuticalsL's management efficiency ratios could be used to measure how well Zentalis PharmaceuticalsL manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.55. The value of Return On Capital Employed is expected to slide to -0.54. At this time, Zentalis PharmaceuticalsL's Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 7.2 M this year, although the value of Non Current Assets Total will most likely fall to about 56.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| MSc MBA | Inozyme PharmaInc | 52 | |
| Ryan Baker | Iteos TherapeuticsInc | N/A | |
| Shane MBA | Olema Pharmaceuticals | 50 | |
| Matthew Gall | Iteos TherapeuticsInc | 46 | |
| Nello MD | Kymera Therapeutics | 46 | |
| Jared MD | Kymera Therapeutics | 59 | |
| Keith CPA | Syndax Pharmaceuticals | 53 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Brittany Mccleery | Sana Biotechnology | N/A | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Stefan Riley | Inozyme PharmaInc | N/A | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Melissa Brody | Kymera Therapeutics | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Joanne MD | Iteos TherapeuticsInc | 52 | |
| Courtney Dugan | Olema Pharmaceuticals | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.29 |
Zentalis PharmaceuticalsL Leadership Team
Elected by the shareholders, the Zentalis PharmaceuticalsL's board of directors comprises two types of representatives: Zentalis PharmaceuticalsL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zentalis. The board's role is to monitor Zentalis PharmaceuticalsL's management team and ensure that shareholders' interests are well served. Zentalis PharmaceuticalsL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zentalis PharmaceuticalsL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Bunker, CoFounder Officer | ||
| Carrie MD, Chief Officer | ||
| Adrian MD, Executive Development | ||
| Mark Lackner, Chief Strategy | ||
| Kimberly Freeman, Chief Officer | ||
| Cameron MBA, President CoFounder | ||
| Adam Levy, VP Relations | ||
| Melissa MBA, CFO Treasurer | ||
| Kimberly MD, CEO Director | ||
| Andrea JD, General Secretary | ||
| Diana MD, Chief Director | ||
| PharmD Rasbach, Chief Officer | ||
| Meena Rao, VP Assurance |
Zentalis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zentalis PharmaceuticalsL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 454.93 M | ||||
| Shares Outstanding | 70.96 M | ||||
| Shares Owned By Insiders | 4.27 % | ||||
| Shares Owned By Institutions | 95.73 % | ||||
| Number Of Shares Shorted | 15.53 M | ||||
| Price To Book | 2.18 X | ||||
| EBITDA | (252.55 M) | ||||
| Net Income | (292.19 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zentalis PharmaceuticalsL is a strong investment it is important to analyze Zentalis PharmaceuticalsL's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis PharmaceuticalsL's future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis PharmaceuticalsLlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Zentalis Stock analysis
When running Zentalis PharmaceuticalsL's price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.47) | Return On Assets (0.29) | Return On Equity (0.67) |
The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis PharmaceuticalsL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.